Broker Presentation May 2015
Melbourne, April 29, 2015 AEST (ABN Newswire) - Compumedics Limited (
ASX:CMP) announce the Broker Presentation for May 2015 with significant highlights.
Investor Overview
- Core business: returned to growth.
- Neurology growth opportunity: New market for CMP. We have the leading brain source localisation software.
- Asian EEG - largest segment of $886.8 m brain monitoring device market
- Asian EEG - 2013 $81.8m PA to 2018 $133.0m by 2018, CAGR: 10.40% (1)
- Trend towards Home Sleep Testing (HST) - CMP well positioned - growing market (2)(3)
- eHealth: Moving Compumedics' proprietary technology to the cloud. $10m of contracts already won.
- Spin offs/strategic decisions to unlock significant value for shareholders
- FY15 guidance: $33m sales, revenue growth >10%, EBITDA $3.5-4m, NPAT $1.8-$2m.
Compumedics is a leading global, innovative developer and manufacturer of medical devices for:
- Diagnosing sleep disorders
- Monitoring neurological disorders including long-term epilepsy monitoring (LTEM)
- Highly sophisticated brain research
- Ultrasonic monitoring of blood flow through the brain (Transcranial Doppler [TCD])
Compumedics is a technological leader in its chosen markets:
#1 Australia sleep & neuro diagnostics device supplier
#1Japan sleep diagnostics device supplier
#1 China sleep diagnostic device supplier to China's premier facilities & #1 TCD device supplier
#3 USA sleep diagnostic device supplier and emerging #3 supplier for neurological monitoring devices
- Compumedics has a rich intellectual property portfolio
- Compumedics e-Health platform is the next growth phase in the company's development
- Compumedics listed ASX Dec 21, 2000
To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-CMP-422516.pdf
About Compumedics Limited
Compumedics Limited (ASX:CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.
Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia's exporter of the year and has been recognised as a Top 100 Innovator by both German and Australian Governments.
Follow Compumedics on Twitter at @Compumedics
| ||
|
